SCHEMBL18173531

SCHEMBL18173531

CCOC(C)Oc1cc(-c2ccco2)cc(OC)c1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.38
MAPK1 P28482 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TP53 P04637 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
MAPT P10636 4/20 0.37
TSHR P16473 3/20 0.37
PDE10A Q9Y233 3/20 0.37
PDE2A O00408 1/20 0.37
PDE5A O76074 1/20 0.37
KDM4E B2RXH2 6/20 0.36
ALDH1A1 P00352 4/20 0.36
HPGD P15428 4/20 0.36
HSD17B10 Q99714 3/20 0.36
LMNA P02545 2/20 0.36
RAB9A P51151 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2389984 0.83 ERN1 (0.56) ERN1SMN1; SMN2MAPK1MEN1KMT2A
SCHEMBL18173532 0.77 ERN1 (0.43) ERN1SMN1; SMN2MAPK1MEN1KMT2A
SCHEMBL18173535 0.73 ERN1 (0.57) ERN1SMN1; SMN2MAPK1MEN1KMT2A
SCHEMBL2387911 0.72 KDM4E (0.59) ERN1SMN1; SMN2MAPK1MEN1KMT2A
SCHEMBL17471104 0.71 ERN1 (0.45) ERN1SMN1; SMN2MAPK1MEN1KMT2A
SCHEMBL2388588 0.69 MAPT (0.64) ERN1SMN1; SMN2MAPK1MEN1KMT2A
SCHEMBL2389780 0.69 ERN1 (0.57) ERN1SMN1; SMN2MAPK1MEN1KMT2A
SCHEMBL2388856 0.69 MAPT (0.53) ERN1SMN1; SMN2MAPK1MEN1KMT2A
SCHEMBL2388038 0.68 MAPT (0.52) ERN1SMN1; SMN2MAPK1MEN1KMT2A
SCHEMBL2387527 0.68 ERN1 (0.56) ERN1SMN1; SMN2MAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3285760-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS Omeros Corporation (US) 2018-02-28 EP disclosed
US-9879002-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2018-01-30 US disclosed
US-9879002-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2018-01-30 US disclosed
US-9879002-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2018-01-30 US disclosed
US-20170022190-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION 2017-01-26 US disclosed
US-20170022190-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION 2017-01-26 US disclosed
WO-2016172573-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2016-10-27 WO disclosed
WO-2016172573-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2016-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022190-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS PDE10A, PDE9A, PDE7A ERN1 4596/4885SMN1; SMN2 556/4885MAPK1 3901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.